trastuzumab

Ligand id: 5082

Name: trastuzumab

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: trastuzumab

Classification
Compound class Antibody
Approved drug? Yes (FDA (1998), EMA (2000))
International Nonproprietary Names
INN number INN
7637 trastuzumab
Synonyms
D5v8 | Herceptin® | R-597
Comments
Trastuzumab is a humanized IgG1κ monoclonal antibody targeting HER2.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.

Biosimilars:
NameTrade nameCompanyClinical PhaseIndications
trastuzumab-dkst; MYL-1401OHertraz; Canmab; OgivriMylan and Biocon Approved in India, FDA 2017, EMA 2018 (Ogivri)Breast cancer
trastuzumab-pkrb; CT-P6Herzuma; CredimaCelltrionApproved in S Korea, EMA & FDA 2018Breast cancer
trastuzumab-dttb; SB3OntruzantSamsung BioepisApproved (EMA 2017, FDA 2019)Eligible indications as per originator
trastuzumab-beta; ABP-980 [3] KanjintiAmgenApproved (EMA 2018)Breast and gastro/esophageal cancers
HLX02 Shanghai Henlius BiotechPh 3 (NCT03084237)Breast cancer
trastuzumab-qyyp; PF-05280014TrazimeraPfizerApproved (FDA 2019; see REFLECTIONS B327-02 trial NCT01989676)Breast and gastro/esophageal cancers
Database Links
Specialist databases
IMGT/mAb-DB 97
Other databases
GtoPdb PubChem SID 178101775
PubChem SID 178101775
Search PubMed clinical trials trastuzumab
Search PubMed titles trastuzumab
Search PubMed titles/abstracts trastuzumab
Wikipedia Trastuzumab